Skip to main content
Springer logoLink to Springer
. 2020 Nov 12;15(6):807. doi: 10.1007/s11523-020-00772-4

Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

Dietger Niederwieser 1,2,3,✉, Caroline Hamm 4, Patrick Cobb 5, Mindy Mo 6, Cecily Forsyth 7, Alessandra Tucci 8, Vladimir Hanes 6, Vincent Delwail 9, Roman Hajek 10, David Chien 6
PMCID: PMC7701060  PMID: 33180232

Correction to: Targeted Oncology (2020) 15:599–611 10.1007/s11523-020-00748-4

Page 608, 4 Discussion, right column, second paragraph: The sentence, which previously read:

“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 0.3 to 11.2%)”.

should read:

“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B-cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 9.3 to 11.2%)”.

The original article has been updated.


Articles from Targeted Oncology are provided here courtesy of Springer

RESOURCES